BiotechTube

RO7248824

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angelman Syndrome

Conditions

Angelman Syndrome

Trial Timeline

Apr 29, 2021 → Aug 1, 2022

NCT ID
NCT04863794

About RO7248824

RO7248824 is a phase 1 stage product being developed by Roche for Angelman Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04863794. Target conditions include Angelman Syndrome.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT04863794Phase 1Completed
NCT04428281Phase 1Completed

Competing Products

9 competing products in Angelman Syndrome

See all competitors
ProductCompanyStageHype Score
RO7248824RochePhase 1
33
AlogabatRochePhase 2
52
ION582Ionis PharmaceuticalsPhase 1/2
38
ION582 + PlaceboIonis PharmaceuticalsPhase 3
74
GTX-102Ultragenyx PharmaceuticalPhase 3
72
GTX-102Ultragenyx PharmaceuticalPhase 3
72
GTX-102Ultragenyx PharmaceuticalPhase 2
47
GTX-102Ultragenyx PharmaceuticalPhase 1/2
36
NNZ-2591Neuren PharmaceuticalsPhase 2
47

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85